Contribution of Animal Models and Preclinical Human Studies to Medication Development for Nicotine Dependence

Animal and Translational Models for CNS Drug Discovery

Volumn , Issue , 2008, Pages 179-219

  Markou, Athina ^a   Chiamulera, Christian V ^b   West, Robert J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951013053     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373861-5.00026-6     Document Type: Chapter

References (254)

1. World Health Organisation (2002) World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organisation
2. H. Bronnum-Hansen and K. Juel (2002) [Health life years lost due to smoking]. Ugeskr Laeger 164 3953-3958.
3. R. Doll, R. Peto, J. Boreham and I. Sutherland (2004) Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 328 1519.
4. R. West (2006) Tobacco control: present and future. Br Med Bull 77-78 123-136.
5. International Agency for Research on Cancer (2002). Tobacco Smoke and Involuntary Smoking IARC Press Lyon (France).
6. U.S. Department of Health and Human Services (2004). The Health Consequences of Smoking: A Report of the Surgeon General, U.S. Public Health Service, National Center for Chronic Disease Prevention and Health Promotion Atlanta
7. G.C. Roman (2005) Vascular dementia prevention: A risk factor analysis. Cerebrovasc Dis 20(Suppl. 2), 91-100.
8. J.M. Seddon, S. George and B. Rosner (2006) Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: The US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 124 995-1001.
9. C. Power, J. Frank, C. Hertzman, G. Schierhout and L. Li (2001) Predictors of low back pain onset in a prospective British study. Am J Public Health 91 1671-1678.
10. R.E. Watkins and A.J. Plant (2006) Does smoking explain sex differences in the global tuberculosis epidemic? Epidemiol Infect 134 333-339.
11. C. Meisinger, A. Doring, B. Thorand and H. Lowel (2006) Association of cigarette smoking and tar and nicotine intake with development of type 2 diabetes mellitus in men and women from the general population: The MONICA/KORA Augsburg Cohort Study. Diabetologia 49 1770-1776.
12. P. Boffetta, B. Aagnes, E. Weiderpass and A. Andersen (2005) Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer 114 992-995.
13. L.S. Wakschlag, K.E. Pickett, K.E. Kasza and R. Loeber (2006) Is prenatal smoking associated with a developmental pattern of conduct problems in young boys? J Am Acad Child Adolesc Psychiatry 45 461-467.
14. A.M. Moller, N. Villebro, T. Pedersen and H. Tonnesen (2002) Effect of preoperative smoking intervention on postoperative complications: A randomised clinical trial. Lancet 359 114-117.
15. J.A. Critchley and B. Unal (2003) Health effects associated with smokeless tobacco: A systematic review. Thorax 58 435-443.
16. Royal College of Physicians of London (2000) Nicotine Addiction in Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians of London
17. U.S. Department of Health and Human Services (1988). The Health Consequences of Smoking: Nicotine Addiction – A Report of the Surgeon General [DHHS Publication No. (CDC) 88-8406]. Rockville, MD: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health.
18. R. West and S. Shiffman (2007) Smoking Cessation. Abingdon: Health Press
19. I. Karp, J. O’Loughlin, R.F. Tyndale and G. Paradis (2006) Risk factors for tobacco dependence in adolescent smokers. Tob Contr 15 199-204.
20. Rodriguez, D., Tercyak, K.P., and Audrain-McGovern, J. (2007). Effects of inattention and hyperactivity/impulsivity symptoms on development of nicotine dependence from mid adolescence to young adulthood. J Pediatr Psychol (in press).
21. O.F. Pomerleau (1995) Individual differences in sensitivity to nicotine: Implications for genetic research on nicotine dependence. Behav Genet 25 161-177.
22. B. Buisson and D. Bertrand (2002) Nicotine addiction: The possible role of functional upregulation. Trends Pharmacol Sci 23 130-136.
23. G. Di Chiara (1998) A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol 12 54-67.
24. P.J. Kenny and A. Markou (2001) Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav 70 531-549.
25. R.J. West and M.A. Russell (1985) Pre-abstinence smoke intake and smoking motivation as predictors of severity of cigarette withdrawal symptoms. Psychopharmacology 87 334-336.
26. A.J. Waters, S. Shiffman, M.A. Sayette, J.A. Paty, C.J. Gwaltney and M.H. Balabanis (2004) Cue-provoked craving and nicotine replacement therapy in smoking cessation. J Consult Clin Psychol 72 1136-1143.
27. B.C. Haberstick, D. Timberlake, M.A. Ehringer, J.M. Lessem, C.J. Hopfer, et al. (2007) Genes, time to first cigarette and nicotine dependence in a general population sample of young adults. Addiction 102 655-665.
28. S. Shiffman, C.A. Elash, S.M. Paton, C.J. Gwaltney, J.A. Paty, et al. (2000) Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. Addiction 95 1185-1195.
29. J.R. Hughes (2007) Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 9 315-327.
30. S. Shiffman (2005) Dynamic influences on smoking relapse process. J Pers 73 1715-1748.
31. L. Dawkins, J.H. Powell, R. West, J. Powell and A. Pickering (2007) A double-blind placebo-controlled experimental study of nicotine: II. Effects on response inhibition and executive functioning. Psychopharmacology 190 457-467.
32. D.I. Lubman, M. Yucel and C. Pantelis (2004) Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction 99 1491-1502.
33. R. West (2006) Theory of Addiction. Oxford: Blackwell
34. West, R. (2006a). COPD Reviews: new approaches to smoking cessation [Online]. Prous Science, Timely Topics in Medicine: Respiratory Diseases [cited December 11 2007], available from: http://www.ttmed.com/respiratory/reviews.cfm?ID_Dis=8andID_Cou=23andID_TA=80
35. D.J. Balfour (2004) The neurobiology of tobacco dependence: A preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res 6 899-912.
36. I.P. Stolerman and M.J. Jarvis (1995) The scientific case that nicotine is addictive. Psychopharmacology 117 2-10.
37. J. Henningfield and S.R. Goldberg (1983) Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 19 989-992.
38. M.D. Swedberg, J.E. Henningfield and S.R. Goldberg (1990) Nicotine dependency: animal studies. S. Wonnacott, M.A.H. Russell, I.P. Stolerman (Eds) Nicotine Psychopharmacology: Molecular, Cellular, and Behavioural Aspects Oxford: Oxford University Press 38-76.
39. J.E. Rose and W.A. Corrigall (1997) Nicotine self-administration in animals and humans: Similarities and differences. Psychopharmacology 130 28-40.
40. D.M. Harvey, S. Yasar, S.J. Heishman, L.V. Panlilio, J.E. Henningfield and S.R. Goldberg (2004) Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology 175 134-142.
41. K.A. Perkins, J.E. Grobe, A. Caggiula, A.S. Wilson and R.L. Stiller (1997) Acute reinforcing effects of low-dose nicotine nasal spray in humans. Pharmacol Biochem Behav 56 235-241.
42. J.R. Hughes, S.W. Gust, R.M. Keenan and J.W. Fenwick (1990) Effect of dose on nicotine’s reinforcing, withdrawal-suppression and self-reported effects. J Pharmacol Exp Ther 252 1175-1183.
43. G. Scherer (1999) Smoking behaviour and compensation: A review of the literature. Psychopharmacology 145 1-20.
44. K.O. Fagerstrom and J.R. Hughes (2002) Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: A review. Nicotine Tob Res 4(Suppl. 2), S73-S79.
45. S.S. Hecht, S.E. Murphy, S.G. Carmella, C.L. Zimmerman, L. Losey, I. Kramarczuk, et al. (2004) Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst 96 107-115.
46. M. Butschky, D. Bailey, J.E. Henningfield and W.B. Pickworth (1995) Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav 50 91-96.
47. J.E. Rose, F.M. Behm, E.C. Westman, R.J. Mathew, E.D. London, T.C. Hawk, et al. (2003) PET studies of the influences of nicotine on neural systems in cigarette smokers. Am J Psychiatry 160 323-333.
48. T.A. Shahan, W.K. Bickel, G.J. Madden and G.J. Badger (1999) Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: a behavioral economic analysis. Psychopharmacology 147 210-216.
49. P.A. Crooks and L.P. Dwoskin (1997) Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 54 743-753.
50. P. Jacob, L. Yu, A.T. Shulgin and N.L. Benowitz (1999) Minor tobacco alkaloids as biomarkers for tobacco use: Comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health 89 731-736.
51. M.T. Bardo, R.A. Bevins, J.E. Klebaur, P.A. Crooks and L.P. Dwoskin (1997) (2)-Nornicotine partially substitutes for (+)-amphetamine in a drug discrimination paradigm in rats. Pharmacol Biochem Behav 58 1083-1087.
52. M.T. Bardo, T.A. Green, P.A. Crooks and L.P. Dwoskin (1999) Nornicotine is self-administered intravenously by rats. Psychopharmacology 146 290-296.
53. A.R. Caggiula, E.C. Donny, A.R. White, N. Chaudhri, S. Booth, M.A. Gharib, et al. (2001) Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav 70 515-530.
54. A.R. Caggiula, E.C. Donny, A.R. White, N. Chaudhri, S. Booth, M.A. Gharib, et al. (2001) Environmental stimuli promote the acquisition of nicotine self-administration in rats. Psychopharmacology 163 230-237.
55. K.A. Perkins, D. Gerlach, J. Vender, J. Grobe, J. Meeker and S. Hutchison (2001) Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. Nicotine Tob Res 3 141-150.
56. J.D. Belluzzi, R. Wang and F.M. Leslie (2005) Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 30 705-712.
57. J. Cao, J.D. Belluzzi, S.E. Loughlin, D.E. Keyler, P.R. Pentel and F.M. Leslie (2007) Acetaldehyde, a major constituent of tobacco smoke, enhances behavioral, endocrine, and neuronal responses to nicotine in adolescent and adult rats. Neuropsychopharmacology 32 2025-2035.
58. Guillem, K., Vouillac, C., Koob, G.F., Cador, M., Stinus, L. (2008). Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion. Biol Psychiatry, 63:158–163.
59. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. fourth ed Washington DC: American Psychiatric Press
60. World Health Organization (1992). International Statistical Classification of Diseases and Related Health Problems, 10th revision, World Health Organization, Geneva.
61. M.A. Geyer and A. Markou (1995) Animal models of psychiatric disorders. F.E. Bloom, D.J. Kupfer (Eds) Psychopharmacology: The Fourth Generation of Progress New York (NY): Raven Press 787-798.
62. M.A. Geyer and A. Markou (2002) The role of preclinical models in the development of psychotropic drugs. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds) Neuropsychopharmacology: The Fifth Generation of Progress Philadelphia: Lippincott Williams and Wilkins 445-455.
63. S.S. Watkins, M.P. Epping-Jordan, G.F. Koob and A. Markou (1999) Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62 743-751.
64. C. Lerman, M.G. LeSage, K.A. Perkins, S.S. O’Malley, S.J. Siegel, N.L. Benowitz, et al. (2007) Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 6 746-762.
65. K.S. Rotenberg, R.P. Miller and J. Adir (1980) Pharmacokinetics of nicotine in rats after single-cigarette smoke inhalation. J Pharm Sci 69 1087-1090.
66. N. Breslau, N. Fenn and E.L. Peterson (1993) Early smoking initiation and nicotine dependence in a cohort of young adults. Drug Alcohol Depend 33 129-137.
67. J.C. Anthony and K.R. Petronis (1995) Early-onset drug use and risk of later drug problems. Drug Alcohol Depend 40 9-15.
68. W. Adriani, S. Spijker, V. Deroche-Gamonet, G. Laviola, M. Le Moal, A.B. Smit, et al. (2003) Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats. J Neurosci 23 4712-4716.
69. W. Adriani, V. Deroche-Gamonet, M. Le Moal, G. Laviola and P.V. Piazza (2006) Preexposure during or following adolescence differently affects nicotine-rewarding properties in adult rats. Psychopharmacology 184 382-390.
70. N. Suto, J.D. Austin and P. Vezina (2001) Locomotor response to novelty predicts a rat’s propensity to self-administer nicotine. Psychopharmacology 158 175-180.
71. N. Doran, B. Spring and D. McChargue (2007) Effect of impulsivity on craving and behavioral reactivity to smoking cues. Psychopharmacology 194 279-288.
72. S.H. Mitchell (2004) Measuring impulsivity and modeling its association with cigarette smoking. Behav Cogn Neurosci Rev 3 261-275.
73. B. Reynolds, M. Patak and P. Shroff (2007) Adolescent smokers rate delayed rewards as less certain than adolescent nonsmokers. Drug Alcohol Depend 90 301-303.
74. I.M. Lipkus, J.C. Barefoot, J. Feaganes, R.B. Williams and I.C. Siegler (1994) A short MMPI scale to identify people likely to begin smoking. J Pers Assess 62 213-222.
75. W.K. Bickel, A.L. Odum and G.J. Madden (1999) Impulsivity and cigarette smoking: Delay discounting in current, never, and ex-smokers. Psychopharmacology 146 447-454.
76. J.D. Burke, R. Loeber, H.R. White, M. Stouthamer-Loeber and D.A. Pardini (2007) Inattention as a key predictor of tobacco use in adolescence. J Abnorm Psychol 116 249-259.
77. Diergaarde, L., Pattij, T., Poortvliet, I., Hogenboom, F., de Vries, W., Schoffelmeer, A.N. et al. (2008). Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats. Biol Psychiatry, 63:301–308.
78. N.E. Paterson and A. Markou (2004) Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats. Psychopharmacology 173 64-72.
79. J.D. Valentine, J.S. Hokanson, S.G. Matta and B.M. Sharp (1997) Self-administration in rats allowed unlimited access to nicotine. Psychopharmacology 133 300-304.
80. M.G. LeSage, D.E. Keyler, D. Shoeman, D. Raphael, G. Collins and P.R. Pentel (2002) Continuous nicotine infusion reduces nicotine self-administration in rats with 23-h/day access to nicotine. Pharmacol Biochem Behav 72 279-289.
81. L.E. O’Dell, S.A. Chen, R.T. Smith, S.E. Specio, R.L. Balster, N.E. Paterson, et al. (2007) Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther 320 180-193.
82. P.J. Kenny and A. Markou (2006) Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology 31 1203-1211.
83. M.P. Epping-Jordan, S.S. Watkins, G.F. Koob and A. Markou (1998) Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393 76-79.
84. A.A. Harrison, Y.T. Liem and A. Markou (2001) Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25 55-71.
85. S. Semenova and A. Markou (2003) Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subsets of rats exhibiting hyposensitivity to the initial effects of clozapine. Biol Psychiatry 54 1249-1264.
86. S. Shiffman, R. West and D. Gilbert (2004) Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res 6 599-614.
87. D.H. Malin, J.R. Lake, P. Newlin-Maultsby, L.K. Roberts, J.G. Lanier, V.A. Carter, et al. (1992) Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43 779-784.
88. D.H. Malin, J.R. Lake, V.A. Carter, J.S. Cunningham, K.M. Hebert, D.L. Conrad, et al. (1994) The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 115 180-184.
89. B.E. Hildebrand, G.G. Nomikos, C. Bondjers, M. Nisell and T.H. Svensson (1997) Behavioral manifestations of the nicotine abstinence syndrome in the rat: Peripheral versus central mechanisms. Psychopharmacology 129 348-356.
90. R. Isola, V. Vogelsberg, T.A. Wemlinger, N.H. Neff and M. Hadjiconstantinou (1999) Nicotine abstinence in the mouse. Brain Res 850 189-196.
91. E. Carboni, L. Bortone, C. Giua and G. Di Chiara (2000) Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend 58 93-102.
92. S. Semenova, A. Bespalov and A. Markou (2003) Decreased prepulse inhibition during nicotine withdrawal in DBA/2J is reversed by nicotine self-administration. Eur J Pharmacol 472 99-110.
93. S. Jonkman, B. Henry, S. Semenova and A. Markou (2005) Mild anxiogenic effects of nicotine withdrawal in mice. Eur J Pharmacol 516 40-45.
94. D.H. Malin, J.R. Lake, T.P. Upchurch, M. Shenoi, N. Rajan and W.E. Schweinle (1998) Nicotine abstinence syndrome precipitated by the competitive nicotinic antagonist dihydro-ß-erythroidine. Pharmacol Biochem Behav 60 609-613.
95. S.S. Watkins, L. Stinus, G.F. Koob and A. Markou (2000) Reward and somatic changes during precipitated nicotine withdrawal in rats: Centrally and peripherally mediated effects. J Pharmacol Exp Ther 292 1053-1064.
96. J.F. Cryan, A.W. Bruijnzeel, K.L. Skjei and A. Markou (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168 347-358.
97. D.H. Malin, J.R. Lake, C.K. Schopen, J.W. Kirk, E.E. Sailer, B.A. Lawless, et al. (1997) Nicotine abstinence syndrome precipitated by central but not peripheral hexamethonium. Pharmacol Biochem Behav 58 695-699.
98. J.R. Hughes (1992) Tobacco withdrawal in self-quitters. J Consult Clin Psychol 60 689-697.
99. S. Shiffman and A.J. Waters (2004) Negative affect and smoking lapses: a prospective analysis. J Consult Clin Psychol 72 192-201.
100. K.L. Skjei and A. Markou (2003) Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats. Psychopharmacology 168 280-292.
101. A. Markou and G.F. Koob (1991) Postcocaine anhedonia: An animal model of cocaine withdrawal. Neuropsychopharmacology 4 17-26.
102. A. Markou and G.F. Koob (1992) Construct validity of a self-stimulation threshold paradigm: Effects of reward and performance manipulations. Physiol Behav 51 111-119.
103. L.S. Covey, A.H. Glassman and F. Stetner (1997) Major depression following smoking cessation. Am J Psychiatry 154 263-265.
104. G. Schulteis, A. Markou, M. Cole and G.F. Koob (1995) Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci USA 92 5880-5884.
105. G. Schulteis, A. Markou, L.H. Gold, L. Stinus and G.F. Koob (1994) Relative sensitivity to naloxone of multiple indices of opiate withdrawal: A quantitative dose-response analysis. J Pharmacol Exp Ther 271 1391-1398.
106. D. Lin, G.F. Koob and A. Markou (1999) Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat: Interactions between the two drugs. Psychopharmacology 145 283-294.
107. D. Lin, G.F. Koob and A. Markou (2000) Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations. Pharmacol Biochem Behav 65 407-417.
108. N.E. Paterson, C. Myers and A. Markou (2000) Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats. Psychopharmacology 152 440-446.
109. C. Spielewoy and A. Markou (2003) Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology 28 1106-1116.
110. S.S. Watkins, G.F. Koob and A. Markou (2000) Neural mechanisms underlying nicotine addiction: Acute positive reinforcement and withdrawal. Nicotine Tob Res 2 19-37.
111. N.E. Paterson, D.J. Balfour and A. Markou (2007) Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci 25 3099-3108.
112. J.F. Cryan, F. Gasparini, G. van Heeke and A. Markou (2003) Non-nicotinic neuropharmacological strategies for nicotine dependence: Beyond bupropion. Drug Discov Today 8 1025-1034.
113. P.J. Kenny, F. Gasparini and A. Markou (2003) Group II metabotropic and a-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther 306 1068-1076.
114. M.E. Carroll, S.T. Lac, M. Asencio and R.M. Keenan (1989) Nicotine dependence in rats. Life Sci 45 1381-1388.
115. S. Semenova, I.P. Stolerman and A. Markou (2007) Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacol Biochem Behav 87 360-368.
116. Jonkman, S., Risbrough, V.B., Geyer, M.A., and Markou, A. (2007). Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology. (in press).
117. D.R. Helton, D.L. Modlin, J.P. Tizzano and K. Rasmussen (1993) Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity. Psychopharmacology 113 205-210.
118. R. Salas, F. Pieri and M. De Biasi (2004) Decreased signs of nicotine withdrawal in mice null for the β4 nicotinic acetylcholine receptor subunit. J Neurosci 24 10035-10039.
119. S. Jonkman and A. Markou (2006) Blockade of nicotinic acetylcholine or dopamine D1-like receptors in the central nucleus of the amygdala or the bed nucleus of the stria terminalis does not precipitate nicotine withdrawal in nicotine-dependent rats. Neurosci Lett 400 140-145.
120. M.I. Damaj, W. Kao and B.R. Martin (2003) Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther 307 526-534.
121. D.H. Epstein, K.L. Preston, J. Stewart and Y. Shaham (2006) Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure. Psychopharmaco-logy 189 1-16.
122. C. Chiamulera, C. Borgo, S. Falchetto, E. Valerio and M. Tessari (1996) Nicotine reinstatement of nicotine self-administration after long-term extinction. Psychopharmacology 127 102-107.
123. N.E. Paterson, W. Froestl and A. Markou (2005) Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-reinstatement of nicotine-seeking in rats. Neuropsychopharmacology 30 119-128.
124. M.E. Liechti, L. Lhuillier, K. Kaupmann and A. Markou (2007) Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci 27 9077-9085.
125. J.L. Katz and S.T. Higgins (2003) The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology 168 21-30.
126. J.R. McKay, M.J. Rutherford, A.I. Alterman, J.S. Cacciola and M.R. Kaplan (1995) An examination of the cocaine relapse process. Drug Alcohol Depend 38 35-43.
127. Y. Buczek, A.D. Le, A. Wang, J. Stewart and Y. Shaham (1999) Stress reinstates nicotine seeking but not sucrose solution seeking in rats. Psychopharmacology 144 183-188.
128. G. Zislis, T.V. Desai, M. Prado, H.P. Shah and A.W. Bruijnzeel (2007) Effects of the CRF receptor antagonist D-Phe CRF(12−41) and the α2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology 53 958-966.
129. M. Gossop, L. Green, G. Phillips and B. Bradley (1990) Factors predicting outcome among opiate addicts after treatment. Br J Clin Psychol 29 209-216.
130. E.A. Gilpin, J.P. Pierce and A.J. Farkas (1997) Duration of smoking abstinence and success in quitting. J Natl Cancer Inst 89 572-576.
131. S.T. Higgins, G.J. Badger and A.J. Budney (2000) Initial abstinence and success in achieving longer term cocaine abstinence. Exp Clin Psychopharmacol 8 377-386.
132. J.R. McKay and R.V. Weiss (2001) A review of temporal effects and outcome predictors in substance abuse treatment studies with long-term follow-ups: Preliminary results and methodological issues. Eval Rev 25 113-161.
133. J.W. Grimm, B.T. Hope, R.A. Wise and Y. Shaham (2001) Neuroadaptation: Incubation of cocaine craving after withdrawal. Nature 412 141-142.
134. L.T. Tran-Nguyen, R.A. Fuchs, G.P. Coffey, D.A. Baker, L.E. O’Dell and J.L. Neisewander (1998) Time-dependent changes in cocaine-seeking behavior and extracellular dopamine levels in the amygdala during cocaine withdrawal. Neuropsychopharmacology 19 48-59.
135. K. Fagerstrom and D.J. Balfour (2006) Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs 15 107-116.
136. S. Shiffman, S.G. Ferguson and C.J. Gwaltney (2006) Immediate hedonic response to smoking lapses: Relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology 184 608-618.
137. T.J. De Vries, W. de Vries, M.C. Janssen and A.N. Schoffelmeer (2005) Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behav Brain Res 161 164-168.
138. Liu, X., Caggiula, A.R., Palmatier, M.I., Donny, E.C., and Sved, A.F. (2008). Cue-induced reinstatement of nicotine-seeking behavior in rats: effect of bupropion, persistence over repeated tests, and its dependence on training dose. Psychopharmacology, 196:365–375.
139. Paterson, N.E., Balfour, D.J., and Markou, A. (2007). Chronic bupropion partially attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Nicotine Tob Res, 25:3099–3108.
140. A.W. Bruijnzeel and A. Markou (2003) Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse 50 20-28.
141. A. Markou, F. Weiss, L.H. Gold, S.B. Caine, G. Schulteis and G.F. Koob (1993) Animal models of drug craving. Psychopharmacology 112 163-182.
142. N.E. Paterson and A. Markou (2005) The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology 179 255-261.
143. N.E. Paterson, S. Semenova, F. Gasparini and A. Markou (2003) The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology 167 257-264.
144. C. Mombereau, L. Lhuillier, K. Kaupmann and J.F. Cryan (2007) GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens ΔFosB accumulation. J Pharmacol Exp Ther 321 172-177.
145. United Nations International Drug Control Programme and World Health Organization (1992) Informal Expert Group Meeting on the Craving Mechanism [report no. V92-54439T]. Geneva: United Nations International Drug Control Programme and World Health Organization
146. R.A. Wise (1988) The neurobiology of craving: implications for the understanding and treatment of addiction. J Abnorm Psychol 97 118-132.
147. G.F. Koob (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13 177-184.
148. S.E. Hyman (1993) Molecular and cell biology of addiction. Curr Opin Neurol Neurosurg 6 609-613.
149. W.A. Corrigall and K.M. Coen (1989) Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 99 473-478.
150. V.J. DeNoble and P.C. Mele (2006) Intravenous nicotine self-administration in rats: Effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology 184 266-272.
151. M. Tessari, E. Valerio, C. Chiamulera and P.M. Beardsley (1995) Nicotine reinforcement in rats with histories of cocaine self-administration. Psychopharmacology 121 282-283.
152. E.C. Donny, A.R. Caggiula, S. Knopf and C. Brown (1995) Nicotine self-administration in rats. Psychopharmacology 122 390-394.
153. M. Shoaib, C.W. Schindler and S.R. Goldberg (1997) Nicotine self-administration in rats: Strain and nicotine pre-exposure effects on acquisition. Psychopharmacology 129 35-43.
154. E.C. Donny, A.R. Caggiula, M.M. Mielke, K.S. Jacobs, C. Rose and A.F. Sved (1998) Acquisition of nicotine self-administration in rats: The effects of dose, feeding schedule, and drug contingency. Psychopharmacology 136 83-90.
155. W.A. Corrigall (1999) Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1 11-20.
156. P.B. Clarke and H.C. Fibiger (1987) Apparent absence of nicotine-induced conditioned place preference in rats. Psychopharmacology 92 84-88.
157. P.J. Fudala, K.W. Teoh and E.T. Iwamoto (1985) Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol Biochem Behav 22 237-241.
158. P.J. Fudala and E.T. Iwamoto (1986) Further studies on nicotine-induced conditioned place preference in the rat. Pharmacol Biochem Behav 25 1041-1049.
159. P.J. Fudala and E.T. Iwamoto (1987) Conditioned aversion after delay place conditioning with nicotine. Psychopharmacology 92 376-381.
160. L.J. Gershell and J.H. Atkins (2003) A brief history of novel drug discovery technologies. Nat Rev Drug Discov 2 321-327.
161. M.I. Damaj and B.R. Martin (1993) Is the dopaminergic system involved in the central effects of nicotine in mice? Psychopharmacology 111 106-108.
162. K.S. Dixit, K.M. Dhasmana, R.C. Saxena and R.P. Kohli (1971) Antagonism of intracerebrally induced nicotinic convulsions in mice: A method for measuring the central antinicotinic activity of CNS acting agents. Psychopharmacologia 19 67-72.
163. L.L. Miner and A.C. Collins (1988) The effect of chronic nicotine treatment on nicotine-induced seizures. Psychopharmacology 95 52-55.
164. L.L. Miner, M.J. Marks and A.C. Collins (1985) Relationship between nicotine-induced seizures and hippocampal nicotinic receptors. Life Sci 37 75-83.
165. P.B. Clarke and R. Kumar (1983) The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol 78 329-337.
166. C. Ksir, R. Hakan, D.P. Hall and K.J. Kellar (1985) Exposure to nicotine enhances the behavioral stimulant effect of nicotine and increases binding of [3H]acetylcholine to nicotinic receptors. Neuropharmacology 24 527-531.
167. P.C. Hatchell and A.C. Collins (1980) The influence of genotype and sex on behavioral sensitivity to nicotine in mice. Psychopharmacology 71 45-49.
168. A. Nordberg and C. Bergh (1985) Effect of nicotine on passive avoidance behaviour and motoric activity in mice. Acta Pharmacol Toxicol (Copenh) 56 337-341.
169. T.J. Gould and J.M. Wehner (1999) Nicotine enhancement of contextual fear conditioning. Behav Brain Res 102 31-39.
170. R. Mansner, E. Alhava and E. Klinge (1974) Nicotine hypothermia and brain nicotine and catecholamine levels in the mouse. Med Biol 52 390-398.
171. M.I. Damaj, W. Glassco, M. Dukat and B.R. Martin (1999) Pharmacological characterization of nicotine-induced seizures in mice. J Pharmacol Exp Ther 291 1284-1291.
172. A. Aguzzi, S. Brandner, U. Sure, D. Rüedi and S. Isenmann (1994) Transgenic and knock-out mice: models of neurological disease. Brain Pathol 4 3-20.
173. E.M. Pich and M.P. Epping-Jordan (1998) Transgenic mice in drug dependence research. Ann Med 30 390-396.
174. M.R. Picciotto, M. Zoli, R. Rimondini, C. Lena, L.M. Marubio, E.M. Pich, et al. (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391 173-177.
175. L.M. Marubio and R. Paylor (2004) Impaired passive avoidance learning in mice lacking central neuronal nicotinic acetylcholine receptors. Neuroscience 129 575-582.
176. A.R. Tapper, S.L. McKinney, R. Nashmi, J. Schwarz, P. Deshpande, C. Labarca, et al. (2004) Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306 1029-1032.
177. B.E. Molles, U. Maskos, S. Pons, M. Besson, P. Guiard, J.P. Guilloux, et al. (2006) Targeted in vivo expression of nicotinic acetylcholine receptors in mouse brain using lentiviral expression vectors. J Mol Neurosci 30 105-106.
178. L.M. Marubio and J. Changeux (2000) Nicotinic acetylcholine receptor knockout mice as animal models for studying receptor function. Eur J Pharmacol 393 113-121.
179. N. Champtiaux and J.P. Changeux (2004) Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. Prog Brain Res 145 235-251.
180. H.A. Lester, C. Fonck, A.R. Tapper, S. McKinney, M.I. Damaj, S. Balogh, et al. (2003) Hypersensitive knockin mouse strains identify receptors and pathways for nicotine action. Curr Opin Drug Discov Devel 6 633-639.
181. L.M. Marubio, M. del Mar Arroyo-Jimenez, M. Cordero-Erausquin, C. Léna, N. Le Novère, A. de Kerchove d’Exaerde, et al. (1999) Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398 805-810.
182. M.I. Damaj, M. Fei-Yin, M. Dukat, W. Glassco, R.A. Glennon and B.R. Martin (1998) Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther 284 1058-1065.
183. T. Rasmussen and M.D. Swedberg (1998) Reinforcing effects of nicotinic compounds: Intravenous self-administration in drug-naive mice. Pharmacol Biochem Behav 60 567-573.
184. I.P. Stolerman, C. Naylor, G.I. Elmer and S.R. Goldberg (1999) Discrimination and self-administration of nicotine by inbred strains of mice. Psychopharmacology 141 297-306.
185. E. Museo and R.A. Wise (1990) Locomotion induced by ventral tegmental microinjections of a nicotinic agonist. Pharmacol Biochem Behav 35 735-737.
186. M.E. Benwell and D.J. Balfour (1992) The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 105 849-856.
187. P.B. Clarke, D.S. Fu, A. Jakubovic and H.C. Fibiger (1988) Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 246 701-708.
188. Y.K. Fung (1990) The importance of nucleus accumbens in nicotine-induced locomotor activity. J Pharm Pharmacol 42 595-596.
189. A. Imperato, A. Mulas and G. Di Chiara (1986) Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132 337-338.
190. D.L. Marshall, P.H. Redfern and S. Wonnacott (1997) Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: Comparison of naive and chronic nicotine-treated rats. J Neurochem 68 1511-1519.
191. Z.J. Yu and L. Wecker (1994) Chronic nicotine administration differentially affects neurotransmitter release from rat striatal slices. J Neurochem 63 186-194.
192. C. Ksir, R.L. Hakan and K.J. Kellar (1987) Chronic nicotine and locomotor activity: Influences of exposure dose and test dose. Psychopharmacology 92 25-29.
193. C. Reavill and I.P. Stolerman (1990) Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br J Pharmacol 99 273-278.
194. M. Nisell, G.G. Nomikos and T.H. Svensson (1994) Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16 36-44.
195. M. Nisell, G.G. Nomikos, P. Hertel, G. Panagis and T.H. Svensson (1996) Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse 22 369-381.
196. F.E. Pontieri, G. Tanda, F. Orzi and G. Di Chiara (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382 255-257.
197. D.J. Balfour, M.E. Benwell, C.E. Birrell, R.J. Kelly and M. Al-Aloul (1998) Sensitization of the mesoaccumbens dopamine response to nicotine. Pharmacol Biochem Behav 59 1021-1030.
198. M. Shoaib and I.P. Stolerman (1992) MK801 attenuates behavioural adaptation to chronic nicotine administration in rats. Br J Pharmacol 105 514-515.
199. K. Chergui, P.J. Charléty, H. Akaoka, C.F. Saunier, J.L. Brunet, M. Buda, et al. (1993) Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 5 137-144.
200. T.E. Robinson and K.C. Berridge (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18 247-291.
201. B. Le Foll and S.R. Goldberg (2006) Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology 184 367-381.
202. W.A. Corrigall and K.M. Coen (1991) Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 104 171-176.
203. W.A. Corrigall and K.M. Coen (1991) Cocaine self-administration is increased by both D1 and D2 dopamine antagonists. Pharmacol Biochem Behav 39 799-802.
204. W.A. Corrigall, K.B. Franklin, K.M. Coen and P.B. Clarke (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107 285-289.
205. W.A. Corrigall, K.M. Coen and K.L. Adamson (1994) Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653 278-284.
206. M. Andreoli, M. Tessari, M. Pilla, E. Valerio, J.J. Hagan and C.A. Heidbreder (2003) Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28 1272-1280.
207. A.Y. Bespalov, O.A. Dravolina, I. Sukhanov, E. Zakharova, E. Blokhina, E. Zvartau, et al. (2005) Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology 49(Suppl. 1), 167-178.
208. M. Tessari, M. Pilla, M. Andreoli, D.M. Hutcheson and C.A. Heidbreder (2004) Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol 499 121-133.
209. O.A. Dravolina, E.S. Zakharova, E.V. Shekunova, E.E. Zvartau, W. Danysz and A.Y. Bespalov (2007) mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology 52 263-269.
210. X. Liu, A.R. Caggiula, S.K. Yee, H. Nobuta, A.F. Sved, R.N. Pechnick, et al. (2007) Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats. Neuropsychopharmacology 32 710-718.
211. W.A. Corrigall, K.M. Coen, K.L. Adamson, B.L. Chow and J. Zhang (2000) Response of nicotine self-administration in the rat to manipulations of mu-opioid and γ-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology 149 107-114.
212. N.E. Paterson, W. Froestl and A. Markou (2004) The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology 172 179-186.
213. W.A. Corrigall and K.M. Coen (1994) Nicotine self-administration and locomotor activity are not modified by the 5-HT3 antagonists ICS 205-930 and MDL 72222. Pharmacol Biochem Behav 49 67-71.
214. A.S. Rauhut, S.N. Mullins, L.P. Dwoskin and M.T. Bardo (2002) Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther 303 664-672.
215. Y. Fu, S.G. Matta, V.G. Brower and B.M. Sharp (2001) Norepinephrine secretion in the hypothalamic paraventricular nucleus of rats during unlimited access to self-administered nicotine: An in vivo microdialysis study. J Neurosci 21 8979-8989.
216. K. Guillem, C. Vouillac, M.R. Azar, L.H. Parsons, G.F. Koob, M. Cador, et al. (2005) Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neurosci 25 8593-8600.
217. A.S. Rauhut, N. Neugebauer, L.P. Dwoskin and M.T. Bardo (2003) Effect of bupropion on nicotine self-administration in rats. Psychopharmacology 169 1-9.
218. M. Shoaib, N. Sidhpura and S. Shafait (2003) Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology 165 405-412.
219. C. Cohen, G. Perrault, C. Voltz, R. Steinberg and P. Soubrié (2002) SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13 451-463.
220. L.H. Ferry (1999) Non-nicotine pharmacotherapy for smoking cessation. Prim Care 26 653-669.
221. T. Bartfai and G.V. Lees (2006) Drug Discovery: From bedside to Wall Street. New York: Elsevier Academic Press
222. D.R. Helton, J.P. Tizzano, J.A. Monn, D.D. Schoepp and M.J. Kallman (1997) LY354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 36 1511-1516.
223. M. Pilla, S. Perachon, F. Sautel, F. Garrido, A. Mann, C.G. Wermuth, et al. (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400 371-375.
224. D.J. Balfour (2001) The pharmacology underlying pharmacotherapy for tobacco dependence: A focus on bupropion. Int J Clin Pract 55 53-57.
225. Y. Shaham, U. Shalev, L. Lu, H. De Wit and J. Stewart (2003) The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology 168 3-20.
226. Y. Shaham, L.K. Adamson, S. Grocki and W.A. Corrigall (1997) Reinstatement and spontaneous recovery of nicotine seeking in rats. Psychopharmacology 130 396-403. [erratum: 133:106].
227. H. de Wit and J. Stewart (1983) Drug reinstatement of heroin-reinforced responding in the rat. Psychopharmacology 79 29-31.
228. M.H. Vitaterna, L.H. Pinto and J.S. Takahashi (2006) Large-scale mutagenesis and phenotypic screens for the nervous system and behavior in mice. Trends Neurosci 29 233-240.
229. L.H. Tecott and E.J. Nestler (2004) Neurobehavioral assessment in the information age. Nat Neurosci 7 462-466.
230. J.C. Crabbe and R.G. Morris (2004) Festina lente: Late-night thoughts on high-throughput screening of mouse behavior. Nat Neurosci 7 1175-1179.
231. R.F. Suckow, T.M. Smith, A.S. Perumal and T.B. Cooper (1986) Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Drug Metab Dispos 14 692-697.
232. R.J. Lamb and R.R. Griffiths (1990) Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology 102 183-190.
233. T.E. Wilens, T.J. Spencer, J. Biederman, K. Girard, R. Doyle, J. Prince, et al. (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158 282-288.
234. H. Morowitz (1995) The emergence of complexity. Complexity 1 4.
235. G.E. Swan (1999) Implications of genetic epidemiology for the prevention of tobacco use. Nicotine Tob Res 1(Suppl. 1), S49-S56.
236. E.J. Houtsmuller, J.A. Thornton and M.L. Stitzer (2002) Effects of selegiline (l-deprenyl) during smoking and short-term abstinence. Psychopharmacology 163 213-220.
237. A.A. Strasser, R.L. Ashare, L.T. Kozlowski and W.B. Pickworth (2005) The effect of filter vent blocking and smoking topography on carbon monoxide levels in smokers. Pharmacol Biochem Behav 82 320-329.
238. J. Foulds, J. Stapleton, C. Feyerabend, C. Vesey, M. Jarvis and M.A. Russell (1992) Effect of transdermal nicotine patches on cigarette smoking: A double blind crossover study. Psychopharmacology 106 421-427.
239. R. West and P. Hajek (2004) Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacology 177 195-199.
240. N.L. Benowitz, S. Zevin and P. Jacob (1998) Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 287 958-962.
241. J.D. Killen and S.P. Fortmann (1997) Craving is associated with smoking relapse: Findings from three prospective studies. Exp Clin Psychopharmacol 5 137-142.
242. R.J. West, P. Hajek and M. Belcher (1989) Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 19 981-985.
243. R. West, M. Ussher, M. Evans and M. Rashid (2006) Assessing DSM-IV nicotine withdrawal symptoms: A comparison and evaluation of five different scales. Psychopharmacology 184 619-627.
244. K. Cahill, L.F. Stead and T. Lancaster (2007) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 1 CD006103.
245. S.G. Gourlay, L.F. Stead and N.L. Benowitz (2004) Clonidine for smoking cessation. Cochrane Database Syst Rev 3 CD000058.
246. J. Hughes, L.F. Stead and T. Lancaster (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev 1 CD000031.
247. C. Silagy, T. Lancaster, L. Stead, D. Mant and G. Fowler (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 3 CD000146.
248. West, R., Baker, C., Capellerri, J., Bushmakin, A. (2008). Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology, 197:371–377.
249. W. Zatonski, M. Cedzynska, P. Tutka and R. West (2006) An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob Control 15 481-484.
250. R. West, P. Hajek and A. McNeill (1991) Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers clinic. Psychopharmacology 104 91-96.
251. M. Unrod, T. Cook, M.G. Myers and S.A. Brown (2004) Smoking cessation efforts among substance abusers with and without psychiatric comorbidity. Addict Behav 15(Suppl 3), S588-sS589.
252. R. West and M. Jarvis (2005) Tobacco smoking and mental disorder. Ital J Psychiatry Behav Sci 15 10-17.
253. A. Markou, T.R. Kosten and G.F. Koob (1998) Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology 18 135-174.
254. T.P. George, M.J. Sernyak, D.M. Ziedonis and S.W. Woods (1995) Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 56 344-346.